Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GUSB | P08236 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vp-14637 SCHEMBL29351615 | 0.86 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| Vp-14637 SCHEMBL16743389 | 0.86 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| Vp-14637 SCHEMBL20741449 | 0.86 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7070861 | 0.79 | ALDH1A1 (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL10106495 | 0.79 | GAA (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL22788662 | 0.77 | KDM4E (0.49) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7067443 | 0.77 | ALDH1A1 (0.45) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL7068147 | 0.76 | ALDH1A1 (0.41) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL642652 | 0.74 | GAA (0.43) | GAAKDM4EHPGDGFERALDH1A1 | |
| SCHEMBL6215111 | 0.74 | GAA (0.40) | GAAKDM4EHPGDGFERALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | GAA 305/4885KDM4E 3876/4885HPGD 1593/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | GAA 305/4885KDM4E 3876/4885HPGD 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.